Brief: Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress

Ampio Pharmaceuticals

02/12/2020 14:18

Dec 2 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO'S PHASE I STUDY FOR INHALED AMPION ADVANCES TO
COMPLETING
ENROLLMENT OF COVID-19 PATIENTS WITH RESPIRATORY DISTRESS
    * AMPIO PHARMACEUTICALS- AP-014 PHASE I INHALED AMPION STUDY
IN
COVID-19 PATIENTS IS PROCEEDING TO FULL OPEN ENROLLMENT
FOLLOWING CLEARANCE BY SMC
    * AMPIO PHARMACEUTICALS - AMPION TRIAL CAN NOW ACCELERATE TO
COMPLETE ENROLLMENT OF REMAINING 34 PATIENTS AT SPEED OF
RECRUITMENT

Source text for Eikon:  ID:nPn4TP6Dya 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))